- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
All New Products Listed Chronologically
| 製品コード | 製品名称 | 製品説明 | 添加時期 |
|---|---|---|---|
| E8328 | Ro24-7429 | Ro24-7429 is a benzodiazepine derivative that acts as a potent, orally active antagonist of HIV-1's Tat transactivator protein, disrupting viral replication by inhibiting Tat-mediated transactivation of the HIV-1 long terminal repeat (LTR) promoter. It also inhibits RUNX1 (runt-related transcription factor 1), contributing to antifibrotic effects by reducing fibrosis markers in models like bleomycin-induced pulmonary fibrosis, alongside anti-inflammatory properties. | Mar 10 2026 |
| P1259 | Cagrilintide | Cagrilintide is a long-acting acylated amylin analogue functioning as a nonselective agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). Its dual action promotes satiety, slows gastric emptying, and reduces food intake through brain-mediated pathways with the potential to treat obesity. | Mar 10 2026 |
| E4671 | ML334 | ML334 (LH601A) is a potent, cell-permeable activator of NRF2 that disrupts the Keap1-NRF2 protein-protein interaction by binding the Keap1 Kelch domain with a Kd of 1 μM, promoting NRF2 nuclear translocation and antioxidant gene expression. | Mar 08 2026 |
| E6698 | STL1267 | STL1267 is a potent agonist of REV-ERB, with Ki of 0.16 µM for REV-ERBα that crosses the blood-brain barrier, enhancing NCoR corepressor recruitment to repress circadian and metabolic genes. | Mar 08 2026 |
| E6697 | PACMA 31 | PACMA 31 is an irreversible, orally active inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. It covalently binds PDI's active-site cysteines, inhibiting reductase/isomerase activity in a dose- and time-dependent manner per insulin aggregation assays. | Mar 01 2026 |
| E6661 | Ontunisertib | Ontunisertib (AGMB-129) is an oral, GI-restricted small molecule inhibitor of ALK5 (TGFβR1), exhibiting the potential to treat fibrostenosing Crohn’s disease (FSCD). It potently blocks pro-fibrotic TGFβ signaling locally in the GI tract via high first-pass metabolism. | Mar 01 2026 |
| E6659 | TYRA-200 | TYRA-200 is an orally bioavailable inhibitor of FGFR1/2/3 that exhibits potential to address clinically observed acquired resistance alterations in FGFR2, such as molecular brake and gatekeeper mutations. | Mar 01 2026 |
| F0854 | Phospho-IRAK4 (Thr345/Ser346) Antibody [G2K20] | Feb 28 2026 | |
| F0654 | Phospho-c-Kit (Tyr703) Antibody [K16C2] | c-Kit (phospho Y703),Phospho-c-Kit (Tyr703) | Feb 28 2026 |
| F1556 | Giantin (Golgi Marker) Antibody [F5N17] | Feb 28 2026 | |
| F1679 | Mouse IgG Antibody [B6P15] | Feb 28 2026 | |
| F2243 | Hepatitis C Virus NS3 Antibody [N19B24] | Feb 28 2026 | |
| F2998 | HIV1 Vif Antibody [P7N1] | Feb 28 2026 | |
| F2605 | Phospho-Tau (Ser422) Antibody [L19H1] | Feb 28 2026 | |
| F0652 | Phospho-TrkA (Y785)/TrkB (Y816) Antibody [G6J11] | Feb 28 2026 | |
| F3766 | MAP2 Antibody [N20A24] | MAP2,MAP-2,Microtubule-Associated Protein 2 (MAP2) | Feb 28 2026 |
| F3821 | Hepatitis C Virus Core Antigen Antibody [N23M4] | Feb 28 2026 | |
| F3556 | Phospho-FoxO1 (T24)/FoxO3a (T32) Antibody [M8K9] | Feb 28 2026 | |
| F3950 | Phospho-ErbB2/HER2 (Tyr1248) Antibody [F22D17] | Feb 28 2026 | |
| F3960 | Measles nucleoprotein Antibody [H14C20] | Feb 28 2026 | |
| F1578 | Phospho-mTOR (Ser2481) Antibody [H20P20] | mTOR (phospho S2481),Phospho-mTOR (Ser2481) | Feb 28 2026 |
| F4774 | Hepatitis B Virus Core Antigen Antibody [F18P11] | Feb 28 2026 | |
| F4625 | Phospho-c-Myc (Ser62) Antibody [M18C23] | Feb 28 2026 | |
| F3057 | Neurofibromin 1 Antibody [J9P10] | Neurofibromin,Neurofibromin 1 | Feb 28 2026 |
| F0728 | FGFR3 Antibody [G21B24] | FGF Receptor 3,FGFR3,FGFR-3 | Feb 28 2026 |
| F4699 | NEDD8 Antibody [F18P17] | Feb 28 2026 | |
| F4689 | Pim-1 Antibody [J10P8] | Feb 28 2026 | |
| F1608 | Cleaved PARP1 Antibody [K10A21] | Feb 28 2026 | |
| F1669 | Androgen Receptor (AR-V7 specific) Antibody [F19P24] | Feb 28 2026 | |
| F5021 | SH2D1A Antibody [C12N16] | Feb 28 2026 | |
| F2956 | Topoisomerase II α+β Antibody [L11B23] | Feb 28 2026 | |
| F2463 | FADD Antibody [P17H10] | Feb 28 2026 | |
| F4241 | SynGAP Antibody [F22M8] | Feb 28 2026 | |
| F1519 | Human Serum Albumin Antibody [L7A9] | ALB,ALB/Albumin,Albumin,Human Serum Albumin | Feb 28 2026 |
| F2474 | Phospho-c-Myc (Thr58) Antibody [L1K9] | c-Myc (phospho T58),Phospho-c-Myc (Thr58) | Feb 28 2026 |
| F4883 | Cdc6 Antibody [L3E6] | Feb 28 2026 | |
| F4265 | p57 Kip2 Antibody [E16C13] | Feb 28 2026 | |
| F4500 | Nek2 Antibody [A24K3] | Feb 28 2026 | |
| F4749 | M6PR Antibody [J18A13] | Feb 28 2026 | |
| F4172 | Argonaute-2 Antibody [K4M16] | Feb 28 2026 | |
| F4112 | ICOS Antibody [A13H14] | Feb 28 2026 | |
| F2478 | C4 binding protein/C4BPB Antibody [K15D12] | Feb 28 2026 | |
| F8550 | SET1A Antibody [K11A18] | Feb 28 2026 | |
| F6299 | MLL2 C-terminal Antibody [L16L11] | Feb 28 2026 | |
| F5660 | EZH1 Antibody [G17M2] | Feb 28 2026 | |
| F5322 | BRCC36 Antibody [M5D3] | Feb 28 2026 | |
| F7125 | LRSAM1 Antibody [K13D2] | Feb 28 2026 | |
| F7401 | SMARCD3/BAF60C Antibody [C13A4] | Feb 28 2026 | |
| F2775 | Phospho-Tau (Ser214) Antibody [M8H2] | Phospho-Tau (Ser214),Tau (phospho S214) | Feb 28 2026 |
| F4859 | VAMP2 Antibody [M16L18] | Feb 28 2026 | |
| F5124 | TMEM111 Antibody [B9P11] | Feb 28 2026 | |
| F7967 | DNA Ligase IV/LIG4 Antibody [H22J17] | Feb 28 2026 | |
| F8516 | Acetyl-β Catenin (Lys49) Antibody [N20A14] | Feb 28 2026 | |
| F1263 | RagC Antibody [H17M14] | Feb 28 2026 | |
| F7104 | MIST1/bHLHa15 Antibody [L9C15] | Feb 28 2026 | |
| F4629 | Rev-Erbα Antibody [N13G12] | Feb 28 2026 | |
| F4865 | Histone H3 (di methyl Lys79) Antibody [F10E18] | Feb 28 2026 | |
| F6850 | PSMD2 Antibody [B5P6] | Feb 28 2026 | |
| F4668 | c-Raf Antibody [K20J19] | Feb 28 2026 | |
| F4860 | Cytokeratin 7 Antibody [H19A10] | Feb 28 2026 | |
| F7245 | eIF6 Antibody [A13F7] | Feb 28 2026 | |
| F4896 | Presenilin 2 Antibody [M18A3] | Feb 28 2026 | |
| F6873 | COBRA1 Antibody [K14G15] | Feb 28 2026 | |
| F4875 | CEA/CD66e Antibody [D17P1] | Feb 28 2026 | |
| F8896 | CBX8 Antibody [E24E8] | Feb 28 2026 | |
| F5142 | TBC1D7 Antibody [D5H17] | Feb 28 2026 | |
| F5830 | Ribosomal Protein L26 Antibody [L15C18] | Feb 28 2026 | |
| F8455 | SDH5 Antibody [F15B20] | Feb 28 2026 | |
| F5051 | SMARCD1/BAF60A Antibody [H10L13] | Feb 28 2026 | |
| F5012 | CD86 Antibody [L10K15] | Feb 28 2026 | |
| F5027 | SIX2 Antibody [E17K9] | Feb 28 2026 | |
| F5031 | CBS Antibody [J23E1] | Feb 28 2026 | |
| F5099 | KGA/GAC Antibody [B11B5] | Feb 28 2026 | |
| F5053 | CDK5 Antibody [H9D2] | Feb 28 2026 | |
| F5056 | ERCC1 Antibody [E18K16] | Feb 28 2026 | |
| F9079 | RhoB Antibody [G12L1] | Feb 28 2026 | |
| F8198 | NPRL2 Antibody [L19L7] | Feb 28 2026 | |
| F8140 | Cyclin C Antibody [J7J21] | Feb 28 2026 | |
| F5125 | Alcohol dehydrogenase 1B Antibody [G20E17] | Feb 28 2026 | |
| F5872 | Sec61B Antibody [E5N6] | Feb 28 2026 | |
| F0150 | Phospho-4E-BP1 (Thr37/46) Antibody [E9G24] | Feb 28 2026 | |
| F0483 | Hamartin/TSC1 Antibody [N1E19] | Hamartin,Hamartin/TSC1 | Feb 28 2026 |
| F0346 | Phospho-PERK (Thr980) Antibody [E16F3] | Feb 28 2026 | |
| F2390 | Flotillin 2 Antibody [A21G15] | Flotillin 2/ESA,Flotillin-2 | Feb 28 2026 |
| F2217 | Bub1 Antibody [N20E21] | Feb 28 2026 | |
| F3029 | MRP4/ABCC4 Antibody [D3L18] | MRP4,MRP4/ABCC4 | Feb 28 2026 |
| F3023 | IL-6 Antibody [F4K18] | IL-6 | Feb 28 2026 |
| F3061 | IL-1β Antibody [J24M1] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F2632 | BRCA1 Antibody [N12F20] | BRCA1 | Feb 28 2026 |
| F3067 | IL-1β Antibody [H12N7] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F2594 | SCF Antibody [K20P17] | Feb 28 2026 | |
| F2836 | SHC Antibody [N2E16] | Feb 28 2026 | |
| F3557 | Phospho-EGF Receptor (Tyr1045) Antibody [F16D14] | Feb 28 2026 | |
| F3443 | Phospho-p130 (Ser672) Antibody [E21C6] | Feb 28 2026 | |
| F3613 | ATP1B2 Antibody [G17J5] | Feb 28 2026 | |
| F3889 | NFAT1 Antibody [L23B6] | Feb 28 2026 | |
| F4143 | Met Antibody [K15N1] | Feb 28 2026 | |
| F4012 | PI3 Kinase p85α Antibody [L7D21] | Feb 28 2026 | |
| F4019 | SIRT7 Antibody [J3K9] | Feb 28 2026 | |
| F4049 | PCK1 Antibody [D3C9] | Feb 28 2026 | |
| F4061 | APAF1 Antibody [L11A23] | Feb 28 2026 | |
| F4104 | IGF-1Rβ Antibody [G20F1] | Feb 28 2026 | |
| F4108 | CSF-1R/M-CSF-R Antibody [P4B9] | Feb 28 2026 | |
| F4354 | Macrophages/Monocytes Antibody [K8D24] | Feb 28 2026 | |
| F4069 | Rab9 Antibody [C1J10] | Feb 28 2026 | |
| F4163 | p22phox Antibody [G20B7] | Feb 28 2026 | |
| F4197 | DARPP32 Antibody [G9D16] | Feb 28 2026 | |
| F4206 | Aurora A Antibody [J10G23] | Feb 28 2026 | |
| F4211 | Claudin-1 Antibody [N2H22] | Feb 28 2026 | |
| F4729 | ATF-3 Antibody [D14J2] | Feb 28 2026 | |
| F4152 | Cyclin A2 Antibody [N5C11] | Feb 28 2026 | |
| F4224 | TNF-R1 Antibody [M22M6] | Feb 28 2026 | |
| F4243 | EBF1 Antibody [D5J14] | Feb 28 2026 | |
| F2137 | Bestrophin/BEST1 Antibody [B12E13] | Bestrophin 1,Bestrophin/BEST1 | Feb 28 2026 |
| F5060 | ATRX Antibody [B2B21] | Feb 28 2026 | |
| F4457 | PLCβ1 Antibody [N12B19] | Feb 28 2026 | |
| F4803 | CD36 Antibody [J12N24] | Feb 28 2026 | |
| F4818 | IP3 receptor Antibody [N14P12] | Feb 28 2026 | |
| F4587 | UNC5B Antibody [H18P14] | Feb 28 2026 | |
| F4691 | DUSP4 Antibody [F2A21] | Feb 28 2026 | |
| F4742 | N-Myc Antibody [C8B13] | Feb 28 2026 | |
| F4814 | SOX10 Antibody [E22E2] | Feb 28 2026 | |
| F4857 | Apolipoprotein E Antibody [L10K14] | Feb 28 2026 | |
| F4863 | iNOS Antibody [G10L10] | Feb 28 2026 | |
| F4873 | CD276 Antibody [P14M24] | Feb 28 2026 | |
| F4878 | TEAD1 Antibody [H6K12] | Feb 28 2026 | |
| F4485 | XRCC4 Antibody [N17K6] | Feb 28 2026 | |
| F4516 | ACK Antibody [B23C14] | Feb 28 2026 | |
| F4677 | TIM-3 Antibody [F19D23] | Feb 28 2026 | |
| F4685 | 5 Lipoxygenase/5-LO Antibody [G15A12] | Feb 28 2026 | |
| F4723 | UBE2I/UBC9 Antibody [P3K8] | Feb 28 2026 | |
| F4736 | PRMT4/CARM1 Antibody [J8A9] | Feb 28 2026 | |
| F4743 | β Arrestin 1 Antibody [A11H23] | Feb 28 2026 | |
| F4746 | Enolase-2 Antibody [F8D21] | Feb 28 2026 | |
| F4755 | CD62L/L-Selectin Antibody [H14P17] | Feb 28 2026 | |
| F4763 | Basic FGF Antibody [L15D6] | Feb 28 2026 | |
| F5088 | RGS2 Antibody [L2C7] | Feb 28 2026 | |
| F5091 | Transgelin 2 Antibody [D20N10] | Feb 28 2026 | |
| F4146 | Phospho-Stat5 (Tyr694) Antibody [L6J15] | Feb 28 2026 | |
| F4174 | Stat1 Antibody [G13B13] | Feb 28 2026 | |
| F4052 | PKM Antibody [F7K24] | Feb 28 2026 | |
| F3968 | Phospho-EGFR (Tyr1101) Antibody [A24A1] | Feb 28 2026 | |
| F4185 | Axl Antibody [P12M12] | Feb 28 2026 | |
| E4770 | Jedi2 | Jedi2 is an activator of the Piezo1 channel that binds to mouse Piezo1 protein with a Kd of 2770 μM. | Feb 27 2026 |
| E6712 | PYCR1-IN-1 | PYCR1-IN-1 (compound 4) is an inhibitor of pyrroline-5-carboxylate reductase 1 (PYCR1) with an IC50 of 8.8 µM. It significantly reduce the levels of proline within a breast cancer cell line and exhibits anti-cell proliferation effect. | Feb 26 2026 |
| E6708 | HQ461 | HQ461 is a molecular glue degrader that promotes CDK12-DDB1-CUL4-RBX1 interaction, causing polyubiquitination and degradation of Cyclin K (CCNK). HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death. | Feb 26 2026 |
| E6637 | YCT529 | YCT-529 is a selective antagonist of retinoic acid receptor alpha (RARα) developed as a pyrrole-linked analog that potently inhibits RARα with an IC50 of 1.2 nM and greater than 300-fold selectivity over RARβ and RARγ. It also serves as oral non-hormonal male contraceptive effectively reduces sperm counts in mice and non-human primates by targeting the retinoid signaling pathway essential for spermatogenesis. | Feb 11 2026 |
| E6630 | NT-0527 | NT-0527 is a potent, specific, and brain-penetrant inhibitor of the NLRP3 inflammasome with oral bioavailability and demonstrated efficacy in an in vivo model of inflammation. | Feb 08 2026 |
| S8827 | Diprovocim | Diprovocim is a potent synthetic agonist that activates the human TLR1/TLR2 heterodimer with an EC50 of 110 pM in THP-1 cells. It also exhibits significant potential as an immune adjuvant. | Feb 04 2026 |
| E6670 | AC-4-130 | AC-4–130 is a potent, selective inhibitor of the STAT5 SH2 domain that directly binds to STAT5, blocking its phosphorylation, dimerization, and nuclear translocation. It acts by disrupting STAT5-dependent gene transcription, effectively reducing pathological STAT5 activity in acute myeloid leukemia (AML). | Feb 03 2026 |
| E6675 | MC3482 | MC3482 is a specific, cell-permeable inhibitor of SIRT5 that mitigates microglia-induced neuroinflammation and neuronal apoptosis by regulating Annexin-A1 succinylation. It significantly improves long-term sensorimotor and cognitive function, exhibiting potential for anti-ischemic stroke treatment. | Feb 03 2026 |
| E6509 | AR420626 | AR420626 is a selective agonist of FFAR3 (GPR41) with an IC50 of 117 nM, that prevents serotonin-induced circular muscle relaxation ex vivo and defecation in vivo. | Feb 03 2026 |
| E6626 | STAT3-IN-3 | STAT3-IN-3 is a potent, selective chemical inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that has shown efficacy in mitigating drug resistance. | Feb 03 2026 |
| E8326 | HNHA | HNHA (N-hydroxy-7-(2-naphthylthio) heptanomide) is a cell-permeable inhibitor of histone deacetylase (HDAC) activity, a key enzyme in gene expression and carcinogenesis with an IC50 of 100 nM. It also exhibits anti-tumor activity both in vitro and in vivo. | Feb 03 2026 |
| E6726 | N-Hydroxysuccinimide | N-Hydroxysuccinimide (HOSu; 1-Hydroxy-2,5-pyrrolidinedione) is a crucial reagent that forms NHS esters via DCC-mediated carboxylic acid activation. These esters enable covalent protein/antibody coupling to surfaces through primary amine reactions. It also modifies microfluidic SPR sensors for bacterial pathogen detection. | Feb 01 2026 |
| A2177 | Anti-mouse IFNγR (CD119)-Invivo | Jan 26 2026 | |
| A2178 | Anti-mouse/human IL-5-Invivo | Jan 26 2026 | |
| E1822 | Acoramidis hydrochloride | Acoramidis hydrochloride (AG10 hydrochloride) is an orally active, selective kinetic stabilizer of WT-transthyretin (TTR) and V122I mutant transthyretin (TTR), providing effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). | Jan 22 2026 |
| E6699 | Opiranserin hydrochloride | Opiranserin hydrochloride (VVZ-149 hydrochloride) is a non-opioid and non-NSAID analgesic that acts as a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50 of 0.86 μM and 1.3 μM, respectively. | Jan 22 2026 |
| S9883 | RMC-5552 | RMC-5552 is a selective bi-steric inhibitor of mTORC1, with the potential for treating mTORC1-activated tumors. It potently inhibits mTORC1-mediated phosphorylation of pS6K and p4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. | Jan 22 2026 |
| A2176 | Anti-mouse CD8α (53-6.7)-Invivo | Jan 20 2026 | |
| E6671 | CMPD-39 | CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays. | Jan 19 2026 |
| E6515 | ML-60218 | ML-60218 is a broad-spectrum inhibitor of RNA polymerase III (pol III), with an IC50 of 32 μM for Saccharomyces cerevisiae and 27 μM for human pol III. ML-60218 disrupts pre-assembled viroplasms and impedes the formation of new ones, acting independently of de novo transcription of cellular RNAs. | Jan 19 2026 |
| F0040 | CD11b Antibody [F15D4] | CD11b,CD11b/ITGAM,Integrin alphaM [CD11b],Integrin αM/CD11b,ITGAM | Jan 16 2026 |
| F1157 | Phospho-HSF1 (Ser326) Antibody [G8N16] | Jan 16 2026 | |
| F2820 | Apolipoprotein CI/Apo-CI Antibody [N16B24] | Jan 16 2026 | |
| F7497 | PLCβ3 Antibody [E24D14] | Jan 16 2026 | |
| F2552 | HES5 Antibody [A22C15] | Jan 16 2026 | |
| F3700 | Phospho-RKIP (Ser153) Antibody [J22F24] | Jan 16 2026 | |
| F3850 | HDGF Antibody [D15M21] | Jan 16 2026 | |
| F3859 | Extracellular matrix protein 1 Antibody [C12L14] | Jan 16 2026 | |
| F3884 | Phospho-Phospholipase Cγ1/PLC-γ-1 (Tyr783) Antibody [J4J15] | Jan 16 2026 | |
| F4016 | OGT/O-Linked N-Acetylglucosamine Transferase Antibody [E11N9] | Jan 16 2026 | |
| F4050 | Phospho-AKT1 (Thr450) Antibody [H24E24] | Jan 16 2026 | |
| F4614 | RSK1 Antibody [P7B9] | Jan 16 2026 | |
| F4635 | Olig1 Antibody [B9J9] | Jan 16 2026 | |
| F4637 | REST Antibody [G10D4] | Jan 16 2026 | |
| F4640 | SUFU Antibody [B21L1] | Jan 16 2026 | |
| F4642 | IKKε Antibody [K13B1] | Jan 16 2026 | |
| F4647 | Toll-like Receptor 3 Antibody [H22B16] | Jan 16 2026 | |
| F4653 | Mer Antibody [D4A12] | Jan 16 2026 | |
| F4657 | Pyk2 Antibody [L19B9] | Jan 16 2026 | |
| F4679 | Myelin Basic Protein Antibody [E7M20] | Jan 16 2026 | |
| F4684 | Smac/Diablo Antibody [J14F1] | Jan 16 2026 | |
| F4696 | Erk5 Antibody [B13D22] | Jan 16 2026 | |
| F4697 | NFAT3 Antibody [H15F22] | Jan 16 2026 | |
| F4777 | GATA4 Antibody [J18F23] | Jan 16 2026 | |
| F4783 | ISG15 Antibody [E12B6] | Jan 16 2026 | |
| F4800 | FMRP Antibody [C2F21] | Jan 16 2026 | |
| F4808 | GAD65 Antibody [L12H12] | Jan 16 2026 | |
| F4809 | DNAJA1 Antibody [J3K12] | Jan 16 2026 | |
| F4813 | HtrA2/Omi Antibody [H8H4] | Jan 16 2026 | |
| F4828 | FGF2 Antibody [E17H24] | Jan 16 2026 | |
| F4832 | SNF5/SMARCB1 Antibody [D12C14] | Jan 16 2026 | |
| F4843 | Cortactin Antibody [D8L7] | Jan 16 2026 | |
| F4861 | JunD Antibody [K7H15] | Jan 16 2026 | |
| F4862 | EAAT1 Antibody [B6P21] | Jan 16 2026 | |
| F4864 | Acetyl-Histone H4 (Lys12) Antibody [D15E14] | Jan 16 2026 | |
| F4866 | TRAF6BP/TAX1BP1 C-terminal Antibody [J5J4] | Jan 16 2026 | |
| F4867 | MVP Antibody [A3H13] | Jan 16 2026 | |
| F4871 | IKZF3 Antibody [D19G22] | Jan 16 2026 | |
| F4872 | RRM1 Antibody [H3C10] | Jan 16 2026 | |
| F4881 | RPS3 (Ribosome Marker) Antibody [J10K2] | Jan 16 2026 | |
| F4899 | PI 3 Kinase catalytic subunit α/PIK3CA Antibody [C16C18] | Jan 16 2026 | |
| F4977 | ACSF2 Antibody [F15E3] | Jan 16 2026 | |
| F2613 | Phospho-TAK1 (Ser439) Antibody [F17C11] | Jan 16 2026 | |
| F4022 | CD45 Antibody [M13C14] | Jan 16 2026 | |
| F3409 | POLDIP2 Antibody [N1K14] | Jan 16 2026 | |
| F4695 | Phospho-STAT3 (Ser727) Antibody [J17G14] | Jan 16 2026 | |
| F4674 | Acetyl-Histone H4 (Lys16) Antibody [G21H2] | Jan 16 2026 | |
| F0884 | Cyclin B1 Antibody [C9G10] | Jan 16 2026 | |
| F0402 | Phospho-TAK1 (Thr184/187) Antibody [G4C5] | Jan 16 2026 | |
| F3294 | Phospho-AMPKα1 (Ser496) Antibody [K3H21] | Jan 16 2026 | |
| F3995 | Dynein intermediate chain 1/DNAI1 Antibody [E1A7] | Jan 16 2026 | |
| F0250 | Phospho-MEK1/2 (Ser221) Antibody [E14F20] | Jan 16 2026 | |
| F0396 | Phospho-HDAC4 (S246)/5 (S259)/7 (S155) Antibody [H5N6] | Jan 16 2026 | |
| F3990 | TRP2/DCT Antibody [K24G11] | Jan 16 2026 | |
| F4718 | DNMT3B Antibody [K20B15] | Jan 16 2026 | |
| F4740 | HEF1/NEDD9 Antibody [M16B3] | Jan 16 2026 | |
| F2626 | GM130 (cis-Golgi Marker) Antibody [A12L1] | Jan 16 2026 | |
| F3992 | Calsequestrin 1 Antibody [P19M13] | Jan 16 2026 | |
| F4142 | Mcl-1 Antibody [D17H9] | Jan 16 2026 | |
| F0399 | Phospho-LKB1 (Ser428) Antibody [H12K23] | Jan 16 2026 | |
| F0147 | N-Cadherin Antibody [G6B2] | CD325,CD325 (N-Cadherin),N Cadherin,N-Cadherin | Jan 16 2026 |
| F1470 | CGRP Antibody [N20P10] | Calcitonin Gene Related Peptide,Calcitonin Gene-Related Peptide,CGRP | Jan 16 2026 |
| F4467 | Glutathione reductase Antibody [E19C20] | Jan 16 2026 | |
| F1479 | PFKFB2 Antibody [E19B24] | Jan 16 2026 | |
| F4018 | Dicer Antibody [F18A13] | Jan 16 2026 | |
| F4471 | HoxB13 Antibody [E5D22] | Jan 16 2026 | |
| F4472 | N/R-Cadherin Antibody [L18B18] | Jan 16 2026 | |
| F4824 | CBL C-terminal Antibody [A13K3] | Jan 16 2026 | |
| F4829 | P cadherin Antibody [B17B8] | Jan 16 2026 | |
| F4830 | FOXC1 Antibody [A1B22] | Jan 16 2026 | |
| F0849 | Nicastrin Antibody [H21H1] | Jan 16 2026 | |
| F3008 | C/EBPβ Antibody [B2A6] | C/EBP β,C/EBPβ,C/EBPβ (LAP),CEBP Beta | Jan 16 2026 |
| F3301 | NEK9 Antibody [E20D7] | Jan 16 2026 | |
| F5127 | CNBP Antibody [E10D2] | Jan 16 2026 | |
| F4827 | JAK3 Antibody [M5G12] | Jan 16 2026 | |
| F4884 | MUC1 Antibody [F23K8] | Jan 16 2026 | |
| F4916 | ATG4B Antibody [P14M3] | Jan 16 2026 | |
| F6058 | PKCα Antibody [B21A18] | Jan 16 2026 | |
| F4751 | Phospho-MEK1 (Ser298) Antibody [L22P14] | Jan 16 2026 | |
| F4714 | CYR61 Antibody [M15N8] | Jan 16 2026 | |
| F4852 | JARID1A Antibody [E24E4] | Jan 16 2026 | |
| F4917 | GSTP1 Antibody [H6L15] | Jan 16 2026 | |
| F4892 | Rab27A Antibody [P23F7] | Jan 16 2026 | |
| F4694 | PIAS1 Antibody [J24P15] | Jan 16 2026 | |
| F4744 | ATP citrate lyase Antibody [N17N8] | Jan 16 2026 | |
| F4748 | Thrombospondin 1 Antibody [N18C17] | Jan 16 2026 | |
| F4909 | CaMKII-α Antibody [P6K24] | Jan 16 2026 | |
| F4735 | p63 Antibody [C10M16] | Jan 16 2026 | |
| F4738 | FXR1 Antibody [G5P16] | Jan 16 2026 | |
| F4690 | Daxx Antibody [H1F20] | Jan 16 2026 | |
| F4907 | NQO1 Antibody [C17H19] | Jan 16 2026 | |
| F4804 | p47phox Antibody [L8D20] | Jan 16 2026 | |
| F4918 | Phospho-Akt1 (Ser129) Antibody [K23C4] | Jan 16 2026 | |
| F4903 | Bcl10 Antibody [J3K14] | Jan 16 2026 | |
| F5098 | SND1 Antibody [J10N22] | Jan 16 2026 | |
| F5128 | DHX9 Antibody [E8M24] | Jan 16 2026 | |
| F6098 | TCF12/HEB Antibody [G2F21] | Jan 16 2026 | |
| F0428 | Cas9 (S. pyogenes) Antibody [L14C20] | Cas9,CRISPR-Cas9 | Jan 16 2026 |
| F0647 | Phospho-FGF Receptor (Tyr653/654) Antibody [F13P7] | FGFR1 (phospho Y653),Phospho-FGF Receptor (Tyr653/654),Phospho-FGF Receptor 1 (Tyr653/654) | Jan 16 2026 |
| P1262 | Eloralintide (LY-3841136) | エロラリンチド（LY 3841136）はAMYR作動薬であり、2型糖尿病および肥満の研究に有望です。 | Jan 14 2026 |
| E6411 | RP03707 | RP03707は、PROTACベースのKRASG12D分解剤です（赤色：KRASG12D阻害剤 (HY - 134813)、黒色：リンカー、青色：E3リガーゼリガンド）。 | Jan 14 2026 |
| E6653 | AR-C118925XX | AR - C118925XXは選択的P2Y2受容体拮抗薬です。AR - C118925XXはATP誘導性のIL - 6産生とp38のリン酸化を阻害します。AR - C118925XXはまた、ブレオマイシン（HY - 108345）誘導性のマウスの皮膚線維症を阻害します。AR - C118925XXはまた、ATP誘導性の腫瘍増殖を阻害します。 | Jan 14 2026 |
| E6651 | HGC652 | HGC652 is a TRIM21-dependent molecular glue degrader that binds the E3 ubiquitin ligase TRIM21 (Kd ≈ 0.06 µM) to induce a TRIM21–NUP98 ternary complex, driving the ubiquitination and selective degradation of nuclear pore complex proteins like NUP155, leading to nuclear pore collapse and cancer cell death. | Jan 14 2026 |
| P1269 | Pegcetacoplan acetate | PEG化環状ペプチドであるPegcetacoplan acetateは、発作性夜間ヘモグロビン尿症（PNH）の成人を治療するために設計された、補体成分C3/C3bの最初の承認された阻害剤です。C3とC3bに結合して、コンバターゼを介したC3切断を阻害し、C3bオプソニン化（血管外溶血）と下流のMAC形成（血管内溶血）をブロックします。 | Jan 13 2026 |
| E8319 | Ro 48-8071 fumarate | Ro 48-8071 fumarateは、HMG-CoA還元酵素の下流にあるコレステロール生合成におけるラノステロール形成を触媒する重要な酵素である2,3-オキシドスクアレンシクラーゼ (OSC)の強力かつ選択的阻害剤です (IC50 = 6.5 nM)。これは、スタチンで見られるHMG-CoA還元酵素のフィードバックアップレギュレーションなしに細胞内コレステロールレベルを低下させ、LDL-Cを低下させるための明確で自己限定的な調節ループを提供します。さらに、癌モデルにおいてアポトーシスを誘発し、細胞シグナル伝達を阻害することにより、顕著な抗癌特性も示します。 | Jan 13 2026 |
| F2133 | Integrin αVβ3 Antibody [C22M19] | Integrin alpha V beta 3,Integrin alphaVbeta3,Integrin αV/β3/CD51/CD61 | Jan 12 2026 |
| F2423 | MUC5B Antibody [G14E16] | Jan 12 2026 | |
| F2553 | Complex I Immunocapture Antibody [K15L2] | Jan 12 2026 | |
| F2102 | C5b-9 + C5b-8 Antibody [P24G22] | Jan 12 2026 | |
| F2700 | Myelin Proteolipid Protein Antibody [C23K3] | Myelin PLP,PLP1 | Jan 12 2026 |
| F2455 | Thyroglobulin Antibody [K18H12] | Jan 12 2026 | |
| F2673 | SSEA4 Antibody [E20H6] | Jan 12 2026 | |
| F2799 | PLVAP/PV-1 Antibody [E23J22] | Panendothelial Cell Antigen,PLVAP,PLVAP/PV-1 | Jan 12 2026 |
| F2786 | β-defensin 1 Antibody [K23F18] | Jan 12 2026 | |
| F3420 | POMC Antibody [B13A5] | ACTH,POMC | Jan 12 2026 |
| F3505 | Tox/Tox2 Antibody [H10P3] | Jan 12 2026 | |
| F3733 | Claudin18.2 Antibody [L24N19] | Claudin 18,Claudin18.2 | Jan 12 2026 |
| F3595 | CD163L1 Antibody [C10D1] | Jan 12 2026 | |
| F3673 | Laminin α5/LAMA5 Antibody [P21J13] | LAMA5,Laminin alpha 5/LAMA5,Laminin alpha5 | Jan 12 2026 |
| F3698 | Loricrin C-terminal Antibody [D17A11] | Jan 12 2026 | |
| F3937 | Connexin 36 Antibody [L23J6] | Jan 12 2026 | |
| F3922 | Phospho-Tau (Ser262) Antibody [N15P23] | Jan 12 2026 | |
| F3976 | UNC5B Antibody [H5N21] | Jan 12 2026 | |
| F4055 | Recoverin Antibody [L5J18] | Jan 12 2026 | |
| F2094 | Nurr1 Antibody [L9M11] | Jan 12 2026 | |
| F4944 | SCG10/Stathmin-2 Antibody [D11B18] | Jan 12 2026 | |
| F4375 | Na+/H+ Exchanger-1 Antibody [K9D3] | Jan 12 2026 | |
| F4543 | SLC22A2/OCT2 Antibody [D23A15] | Jan 12 2026 | |
| F4584 | NKX6.1 Antibody [N24F3] | Jan 12 2026 | |
| F4799 | AGO4 Antibody [K1B14] | Jan 12 2026 | |
| F4802 | Eg5 Antibody [B24B13] | Jan 12 2026 | |
| F4810 | PEN2 Antibody [E13J21] | Jan 12 2026 | |
| F4821 | GRP94 Antibody [D7B6] | Jan 12 2026 | |
| F4844 | CYP27A1 Antibody [G12G9] | Jan 12 2026 | |
| F8698 | NF-κB2 p100/p52 Antibody [D6C15] | Jan 12 2026 | |
| F0550 | NMDA Receptor 2B/GluN2B Antibody [K20B17] | NMDA Receptor 2B (GluN2B),NMDAR2B,NR2B | Jan 12 2026 |
| F0802 | Phospho-HER3/ErbB3 (Tyr1197) Antibody [F15P3] | Jan 12 2026 | |
| F0977 | Phospho-BTK (Tyr223) Antibody [H3N9] | BTK (phospho Y223),Phospho-Btk (Tyr223) | Jan 12 2026 |
| F0959 | Ras (G12V Mutant Specific) Antibody [E10J6] | Jan 12 2026 | |
| F1376 | TAX1BP1 Antibody [B22F23] | Jan 12 2026 | |
| F0384 | Hydroxy-HIF-1α (Pro564) Antibody [P20E16] | Jan 12 2026 | |
| F3001 | Phospho-ErbB3/HER3 (Tyr1289) Antibody [P19F5] | ErbB3 / HER3 (phospho Y1289),Phospho-HER3/ErbB3 (Tyr1289) | Jan 12 2026 |
| F2832 | Rab4-Early Endosome Marker Antibody [G1G11] | Jan 12 2026 | |
| F2898 | HSD17B1 Antibody [C12F18] | Jan 12 2026 | |
| F1247 | SSH1 Antibody [K8K10] | Slingshot homolog 1/SSH1,SSH1 | Jan 12 2026 |
| F3163 | TPH2 Antibody [B20J2] | TPH2,Tryptophan hydroxylase 2 | Jan 12 2026 |
| F3393 | PDK1 Antibody [E12L3] | PDHK1 | Jan 12 2026 |
| F3224 | Ferritin Heavy Chain Antibody [L13L19] | Ferritin,Ferritin Heavy Chain,FTH1 | Jan 12 2026 |
| F3707 | Na(+)/K(+)-transporting ATPase (pan α subunit) Antibody [G11K19] | ATP1A1/ATP1A2/ATP1A3/ATP1A4 | Jan 12 2026 |
| F3705 | Flt3 ligand/Flt3L Antibody [D18L13] | Jan 12 2026 | |
| F3877 | STAT2 Antibody [M23L9] | Jan 12 2026 | |
| F3542 | Cyclin E1 Antibody [E13M10] | Cyclin E,Cyclin E1 | Jan 12 2026 |
| F4228 | Phospho-FGF Receptor 1 (Tyr653/654) Antibody [P6D11] | Jan 12 2026 | |
| F4120 | Phospho-p53 (Ser15) Antibody [C9F23] | Jan 12 2026 | |
| F4620 | MMP-3 Antibody [K11K15] | Jan 12 2026 | |
| F4617 | Phospho-Met (Tyr1349) Antibody [D24L22] | Jan 12 2026 | |
| F4207 | Cas9 (S. pyogenes) Antibody [B9K16] | Jan 12 2026 | |
| F4597 | EAAT2 Antibody [C22G14] | Jan 12 2026 | |
| F4786 | NUR77 Antibody [J10J24] | Jan 12 2026 | |
| F5055 | Phospho-Chk1 (Ser296) Antibody [F19D13] | Jan 12 2026 | |
| F4591 | Parvalbumin Antibody [J22P8] | Jan 12 2026 | |
| F4708 | TAZ Antibody [G13C12] | Jan 12 2026 | |
| F4805 | ACSL1 Antibody [D13B22] | Jan 12 2026 | |
| F1630 | ABCA1 Antibody [D20K13] | ABC1,ABCA1 | Jan 12 2026 |
| F3876 | STIM1 Antibody [D10B10] | Jan 12 2026 | |
| F2169 | Osteocalcin Antibody [G12E1] | Jan 12 2026 | |
| F2603 | Wnt3 and Wnt3a Antibody [J20B9] | Jan 12 2026 | |
| F2252 | IL-10 Antibody [G7K6] | Jan 12 2026 | |
| F3186 | LDH-C Antibody [G8C3] | Jan 12 2026 | |
| F2356 | Vitronectin/S-Protein Antibody [G14H11] | Vitronectin,Vitronectin/S-Protein | Jan 12 2026 |
| F3404 | α-Synuclein Antibody [D23J23] | alpha Synuclein,Alpha-synuclein,Synuclein alpha,α-Synuclein | Jan 12 2026 |
| F2441 | Progerin Antibody [J17D10] | Jan 12 2026 | |
| F2790 | HE4 Antibody [D10B8] | Jan 12 2026 | |
| F0377 | EGF Receptor (L858R Mutant Specific) Antibody [B13L21] | Jan 12 2026 | |
| F2021 | Cardiac Troponin I Antibody [L9G3] | Jan 12 2026 | |
| F0975 | Apolipoprotein E Antibody [B14G10] | ApoE (pan),Apolipoprotein E,Apolipoprotein E/ApoE | Jan 12 2026 |
| F3872 | TRPV4 Antibody [M19L9] | Jan 12 2026 | |
| F1149 | Aquaporin 5 Antibody [N15B11] | Aquaporin 5,Aquaporin 5/AQP5 | Jan 12 2026 |
| F4553 | TDO2 Antibody [L23B14] | Jan 12 2026 | |
| F4377 | Src Antibody [M13K12] | Jan 12 2026 | |
| F3639 | BNIP3L/NIX Antibody [E12P3] | Jan 12 2026 | |
| F4820 | USP10 Antibody [C3H16] | Jan 12 2026 | |
| F4801 | BAP1 Antibody [L1A7] | Jan 12 2026 | |
| F1021 | AFP Antibody [M19A22] | AFP,AFP/Alpha fetoprotein,alpha 1 Fetoprotein,alpha-Fetoprotein (AFP) | Jan 12 2026 |
| F5085 | DBT Antibody [C3J21] | Jan 12 2026 | |
| F2308 | CaV1.1 Antibody [G21K18] | CACNA1S,CaV1.1,Dihydropyridine-sensitive Calcium Channel alpha 1 Subunit | Jan 12 2026 |
| F3828 | Human Dectin-1/CLEC7A Antibody [J4K7] | Jan 12 2026 | |
| F3820 | LYVE1 Antibody [C2N8] | Jan 12 2026 | |
| F2838 | Peroxiredoxin 6 Antibody [G12J13] | Peroxiredoxin 6,PRDX6 | Jan 12 2026 |
| F3882 | SRC3 Antibody [G12J12] | Jan 12 2026 | |
| F4632 | Histone H3 (mono methyl Lys27) Antibody [G24J14] | Jan 12 2026 | |
| E6564 | VG-3927 | VG-3927は、強力で選択的かつ脳に浸透するTREM2アゴニストであり、抗炎症性のミクログリア活性化を誘導し、アルツハイマー病（AD）を治療する可能性があります。 | Jan 12 2026 |
| F4372 | Goat/sheep IgG Antibody [N20K2] | Jan 12 2026 | |
| F4819 | SMURF 2 Antibody [A20L4] | Jan 12 2026 | |
| F4826 | FH/Fumarase Antibody [J4P14] | Jan 12 2026 | |
| F4831 | Glutathione Peroxidase 1 Antibody [M21J11] | Jan 12 2026 | |
| F4945 | GBE1 Antibody [P1M6] | Jan 12 2026 | |
| F5002 | Integrin αV Antibody [P12L6] | Jan 12 2026 | |
| F5020 | ApoA1 Antibody [L13J2] | Jan 12 2026 | |
| F5077 | MCAM Antibody [N21F20] | Jan 12 2026 | |
| F6831 | CBX4 Antibody [F18M1] | Jan 12 2026 | |
| F6758 | ORC6 Antibody [E10G21] | Jan 12 2026 | |
| F1719 | MBP tag Antibody [E2A2] | Maltose Binding Protein,MBP tag,MBP-probe | Jan 12 2026 |
| F1681 | E.coli LPS Antibody [M15H2] | Jan 12 2026 | |
| F1647 | α-synuclein aggregate Antibody [C4F17] | Aggregated a-Synuclein,Alpha-synuclein aggregate,SNCA | Jan 12 2026 |
| F2110 | Otoferlin Antibody [J18F12] | Jan 12 2026 | |
| E8330 | NIC3 | NIC3は、がんで過剰発現しているBTB/POZドメイン含有転写コアプレッサーであるnucleus accumbens-associated protein 1 (NAC1)の選択的阻害剤です。これはNAC1のBTBドメイン内の保存されたLeu-90残基に結合し、核小体形成と安定性に不可欠なホモ二量体化を破壊します。 | Jan 05 2026 |
| E8325 | Quadrol | Quadrol（N,N,N′,N′-テトラキス（2-ヒドロキシプロピル）エチレンジアミン、EDTP）は、創傷治癒を促進するための潜在的に有用な活性分子として考慮されている免疫刺激剤です。QuadrolはCa²⁺と複合体を形成し、マクロファージへのCa²⁺の侵入を媒介し、マクロファージの活性化を刺激することができます。 | Jan 05 2026 |
| E8327 | DHBS | DHBS（3,5-ジクロロ-2-ヒドロキシベンゼンスルホン酸ナトリウム）は、血清および尿サンプル中の尿酸の比色定量のため、4-アミノアンチピリン（4-AAP）および過酸化水素（H2O2）と組み合わせて使用されます。 | Jan 05 2026 |
| E6635 | MC3138 | MC3138はSIRT5の選択的活性化因子であり、SIRT5を介したデスシンニル化とデアセチル化を回復させることにより、SIRT5が低いPDAC細胞株およびオルガノイドの増殖を阻害します。 | Jan 04 2026 |
| E0853 | 360A | 360AはG-四鎖体の選択的安定化剤であり、TRAP - G4アッセイにおいてテロメラーゼに対するIC50が300 nMでテロメラーゼ活性を阻害します。 | Dec 31 2025 |
| A2175 | Anti-mouse CD11c-Invivo | Dec 30 2025 | |
| E6667 | JNJ-9350 | 化学プローブであるJNJ - 9350は、スペルミンオキシダーゼ（SMOX）の阻害剤で、IC50値は0.01μMです。JNJ - 9350はまた、ポリアミンオキシダーゼ（PAO）を阻害し、IC50値は0.79μMです。JNJ - 9350は、がんの研究に使用できます。 | Dec 24 2025 |
| E8329 | VQW-765 | VQW - 765（AQW - 051）は、組換え発現ヒトα7ニコチン性アセチルコリン受容体（α7 - nAChR）に対するpKD値が7.56である、選択的かつ経口活性のα7ニコチン性アセチルコリン受容体（α7 - nAChR）アゴニストです。VQW - 765は、in vivoで抗不安薬様効果を示します。VQW - 765は、不安障害および急性業務不安の研究に使用できます。 | Dec 24 2025 |
| E1789 | Asundexian | アスンデキシアン（BAY 2433334）は、経口活性型の凝固第XI因子（FXIa）阻害薬です。アスンデキシアンは、FXIaの活性部位に直接、強力かつ可逆的に結合し、それによってその活性を阻害します。アスンデキシアンは、緩衝液中でヒトFXIaをIC50が1 nMで阻害します。 | Dec 24 2025 |
| E6656 | STAT3-IN-13 | STAT3-IN-13（化合物6f）は強力なSTAT3阻害剤です。STAT3-IN-13は抗増殖効果を有し、KDが0.46μMでSTAT3のSH2ドメインに結合します。STAT3-IN-13はSTAT3のY705のリン酸化と下流の標的遺伝子の発現を阻害します。STAT3-IN-13はin vitroでアポトーシスを誘導し、in vivoで腫瘍の成長と転移を抑制します。STAT3-IN-13はがん研究に使用できます。 | Dec 24 2025 |
| E5872 | BBO-10203 | BBO - 10203は、PI3KαとKRASG12Cの強力な阻害剤であり、PI3KαのRAS結合ドメイン内のCys242に選択的かつ共有結合的に結合し、KRASG12CのGTP結合状態とGDP結合状態の両方を阻害し、IC50は0.031 nM、EC50は0.02 nMである。BBO - 10203は、RASアイソフォームとPI3Kαの相互作用を阻害し、RAS介在性のPI3Kα活性化を阻害し、pERKの発現を低下させ、細胞増殖を抑制し、G1期停止とアポトーシスを誘導する。BBO - 10203は、乳がん、結腸直腸がん、非小細胞肺がんの研究に使用できる。 | Dec 24 2025 |
| E8324 | GE11 | GE11は活性ペプチドであり、コロイド状薬物送達システムと結合して抗腫瘍薬のスマートキャリアとして機能し、癌研究に使用できる。 | Dec 21 2025 |
- First Page
- Previous
-
- Next
- Last Page
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間